Significance of Serum β2-Microglobulin for Survival and Relapse of Patients with Diffuse Large B-Cell Lymphoma in the Rituximab Era
10.19746/j.cnki.issn1009-2137.2025.04.019
- VernacularTitle:利妥昔单抗时代血清β2-微球蛋白对弥漫性大B细胞淋巴瘤患者生存和复发的意义
- Author:
Yu-Ze YANG
1
;
Ya-Ru XU
;
Mei ZHOU
;
Wen-Yan XU
;
Li-Qiang ZHOU
;
Zhen-Xing GUO
Author Information
1. 清华大学医学院,北京 100084;清华大学第一附属医院血液肿瘤科,北京 100016
- Publication Type:Journal Article
- Keywords:
diffuse large B-cell lymphoma;
β2-microglobulin;
survival;
relapse;
rituximab
- From:
Journal of Experimental Hematology
2025;33(4):1057-1062
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the significance of serum β2-microglobulin(β2-MG)for survival and relapse of patients with diffuse large B-cell lymphoma(DLBCL)in the rituximab era.Methods:Clinical data of 92 patients with DLBCL admitted from December 2003 to July 2015 were retrospectively analyzed.The optimal cutoff value of β2-MG levels for predicting prognosis of the DLBCL patients was determined using receiver operating characteristic(ROC)curve.Kaplan-Meier analysis was used to estimate progression-free survival(PFS)and overall survival(OS).Cox logistic regression analysis was used to explore potential prognostic factors associated with survival.Binary logistic regression analysis was used to analyze the relationship between various factors and relapse.Results:The most discriminative cutoff value for β2-MG level was determined to be 2.25 mg/L by the ROC curve.Subgroup analysis showed that patients in the elevated β2-MG(＞2.25 mg/L)group had significantly worse PFS(P=0.006)and a trend toward worse OS compared with those in the low β2-MG(≤2.25 mg/L)group(P=0.053).Univariate analysis showed that elevated β2-MG,age＞60 years,Ann Arbor stage Ⅲ-Ⅳ,as well as IPI score ≥ 3 were associated with worse PFS.Binary logistic regression analysis showed that age＞60 years and β2-M G＞2.25 mg/L were potential influencing factors for relapse of DLBCL patients.Conclusion:Serum β2-MG might be an important predictor for the survival and relapse of DLBCL patients in the rituximab era.
